Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of cancer evolution on immune surveillance and checkpoint inhibitor response
Yin Wu, Dhruva Biswas, Charles Swanton
Seminars in Cancer Biology (2021) Vol. 84, pp. 89-102
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Zhou Chen, Fangfang Han, Yan Du, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 550
Natural killer cells: a promising immunotherapy for cancer
Junfeng Chu, Fengcai Gao, Meimei Yan, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 115
PD-1 defines a distinct, functional, tissue-adapted state in Vδ1+ T cells with implications for cancer immunotherapy
Daniel Davies, Shraddha Kamdar, Richard Woolf, et al.
Nature Cancer (2024)
Open Access | Times Cited: 21
Mechanisms and Strategies of Immunosenescence Effects on Non-Small Cell Lung Cancer (NSCLC) Treatment: A Comprehensive Analysis and Future Directions
Huatao Zhou, Zilong Zheng, Chengming Fan, et al.
Seminars in Cancer Biology (2025) Vol. 109, pp. 44-66
Closed Access | Times Cited: 3
From complexity to clarity: unravelling tumor heterogeneity through the lens of tumor microenvironment for innovative cancer therapy
Sikiru O. Imodoye, Kamoru A. Adedokun, Ibrahim O. Bello
Histochemistry and Cell Biology (2024) Vol. 161, Iss. 4, pp. 299-323
Closed Access | Times Cited: 16
Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia
Agata Pastorczak, Krzysztof Domka, Klaudyna Fidyt, et al.
Cancers (2021) Vol. 13, Iss. 7, pp. 1536-1536
Open Access | Times Cited: 50
Circulating Tumor DNA as a Biomarker for Monitoring Patients with Solid Cancers: Comparison with Standard Protein Biomarkers
Michael J. Duffy, John Crown
Clinical Chemistry (2022) Vol. 68, Iss. 11, pp. 1381-1390
Open Access | Times Cited: 35
Capturing cancer evolution using genetically engineered mouse models (GEMMs)
William Hill, Deborah R. Caswell, Charles Swanton
Trends in Cell Biology (2021) Vol. 31, Iss. 12, pp. 1007-1018
Closed Access | Times Cited: 33
Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination
Lieke L. van der Woude, Mark A.J. Gorris, Inge M. N. Wortel, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 10, pp. e005248-e005248
Open Access | Times Cited: 23
Local γδ T cells: translating promise to practice in cancer immunotherapy
Iva Zlatareva, Yin Wu
British Journal of Cancer (2023) Vol. 129, Iss. 3, pp. 393-405
Open Access | Times Cited: 14
Targeting the epigenetic processes to enhance antitumor immunity in small cell lung cancer
Hao Luo, Jinlu Shan, Hong Zhang, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 960-970
Open Access | Times Cited: 17
Gamma delta T cells and their immunotherapeutic potential in cancer
Stephen G. Cieslak, Reza Shahbazi
Biomarker Research (2025) Vol. 13, Iss. 1
Open Access
HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab
Andrea Ladányi, Barbara Hegyi, Tímea Balatoni, et al.
Pathology & Oncology Research (2022) Vol. 28
Open Access | Times Cited: 12
Spatial profiling of the microenvironment reveals low intratumoral heterogeneity and STK11-associated immune evasion in therapy-naïve lung adenocarcinomas
Hannah Goldschmid, Klaus Kluck, Markus Ball, et al.
Lung Cancer (2023) Vol. 180, pp. 107212-107212
Closed Access | Times Cited: 6
Immune checkpoint expression patterns on T cell subsets in light-chain amyloidosis: VISTA, PD-1, and TIGIT as potential therapeutic targets
Jinghua Wang, Yujie Zhao, Pengjun Liao, et al.
Blood Science (2024) Vol. 6, Iss. 1, pp. e00181-e00181
Open Access | Times Cited: 2
The Role of Natural Killer Cells in Oncolytic Virotherapy: Friends or Foes?
Michael L. Franks, Ju-Hyun An, Jianmei W. Leavenworth
Vaccines (2024) Vol. 12, Iss. 7, pp. 721-721
Open Access | Times Cited: 2
Precision medicine in cancer: A paradigm shift
Richard Rosenquist, Stefan Fröhling, Κώστας Σταματόπουλος
Seminars in Cancer Biology (2022) Vol. 84, pp. 1-2
Closed Access | Times Cited: 10
Clonal Neoantigen: Emerging “Mechanism-based” Biomarker of Immunotherapy Response
John Nemunaitis, Laura Stanbery, David Willoughby, et al.
Cancers (2023) Vol. 15, Iss. 23, pp. 5616-5616
Open Access | Times Cited: 5
Development and Validation of a Gene Mutation-Associated Nomogram for Hepatocellular Carcinoma Patients From Four Countries
Tingping Huang, Tao Yan, Gonghai Chen, et al.
Frontiers in Genetics (2021) Vol. 12
Open Access | Times Cited: 10
Deciphering colorectal cancer immune microenvironment transcriptional landscape on single cell resolution – A role for immunotherapy
Francis Yew Fu Tieng, Learn‐Han Lee, Nurul‐Syakima Ab Mutalib
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Harnessing tumor immunity with cytotoxics: T cells monitoring in mice bearing lung tumors treated with anti-VEGF and pemetrexed-cisplatin doublet
Guillaume Sicard, Dorian Protzenko, S. Giacometti, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 9, pp. 1373-1382
Closed Access | Times Cited: 4
It’s high-time to re-evaluate the value of induced-chemotherapy for reinforcing immunotherapy in colorectal cancer
Shiya Yao, Yuejun Han, Mengxiang Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy
John Nemunaitis, Laura Stanbery, Adam Walter, et al.
Future Oncology (2024) Vol. 20, Iss. 29, pp. 2149-2164
Open Access | Times Cited: 1
Development of a Prognostic Alternative Splicing Signature Associated With Tumor Microenvironment Immune Profiles in Lung Adenocarcinoma
Guangyao Bao, Tian Li, Xiaojiao Guan, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 3
The Link Between Chromosomal Instability and Immunity in Cancer
Laxmi Kumari, Yashwant Kumar, Alka Bhatia
Springer eBooks (2022), pp. 1-20
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top